Therefore, the use of VEGF121, which is involved in tumor growth more specifically than tVEGF-A, including VEGF165, could stratify both the PFS and ORR of anti-PD-1/PD-L1 antibody treatment. This evidence concerns the gene PDCD1 and neoplasm.